FindTrial
Sign In

L19IL2/L19TNF

DRUG5 trials

Sponsors

Philogen S.p.A.

Conditions

BCC - Basal Cell CarcinomaKaposi SarcomaKeratoacanthoma of SkinLocally Advanced Basal Cell CarcinomaLocally Advanced Cutaneous Squamous Cell CarcinomaMalignant Adnexal Tumors of the Skin (MATS)Melanoma Stage IIIMelanoma Stage IV

Phase 2

L19IL2/L19TNF in Skin Cancer Patients
NCT05329792
Philogen S.p.A.BCC - Basal Cell Carcinoma, Kaposi Sarcoma, Keratoacanthoma of Skin +4
Start: 2023-03-09End: 2024-12-31Target: 70Updated: 2023-10-06
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
RecruitingNCT06284590
Philogen S.p.A.Melanoma Stage III, Melanoma Stage IV
Start: 2024-07-12End: 2028-07-31Target: 162Updated: 2024-10-26
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
RecruitingNCT07227350
Philogen S.p.A.Locally Advanced Basal Cell Carcinoma
Start: 2026-06-01End: 2031-02-01Target: 180Updated: 2026-07-06
L19IL2/TNF in Patients With Basal Cell Carcinoma
RecruitingNCT07227870
Philogen S.p.A.Locally Advanced Basal Cell Carcinoma
Start: 2026-09-01End: 2031-02-01Target: 92Updated: 2026-07-21
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
RecruitingNCT07228442
Philogen S.p.A.Locally Advanced Cutaneous Squamous Cell Carcinoma
Start: 2026-09-01End: 2031-02-01Target: 92Updated: 2026-07-21